PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapy
Abstract Background Intravascular large B‐cell lymphoma (IVLBCL) is a rare form of diffuse large B‐cell lymphoma (DLBCL) arising in extranodal sites. PD‐L1 expression of tumor cells has been reported in IVLBCL cells, but its clinicopathological relevance remains to be elucidated. Aims This study was...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-07-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.3104 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850122538218160128 |
|---|---|
| author | Yuka Suzuki Kei Kohno Kosei Matsue Ayako Sakakibara Eri Ishikawa Satoko Shimada Kazuyuki Shimada Seiyo Mabuchi Taishi Takahara Seiichi Kato Shigeo Nakamura Akira Satou |
| author_facet | Yuka Suzuki Kei Kohno Kosei Matsue Ayako Sakakibara Eri Ishikawa Satoko Shimada Kazuyuki Shimada Seiyo Mabuchi Taishi Takahara Seiichi Kato Shigeo Nakamura Akira Satou |
| author_sort | Yuka Suzuki |
| collection | DOAJ |
| description | Abstract Background Intravascular large B‐cell lymphoma (IVLBCL) is a rare form of diffuse large B‐cell lymphoma (DLBCL) arising in extranodal sites. PD‐L1 expression of tumor cells has been reported in IVLBCL cells, but its clinicopathological relevance remains to be elucidated. Aims This study was aimed to reveal the characteristics of PD‐L1+ IVLBCL. Methods and results Neoplastic PD‐L1 expression was examined in 34 cases of IVLBCL and clinicopathological characteristics between patients with PD‐L1+ and PD‐L1− IVLBCL were compared. We assessed PD‐L1 expression with SP142 antibody. Twelve (35%) of 34 cases showed positivity for PD‐L1. The PD‐L1+ group had significantly lower survival rates compared to the PD‐L1− group. The PD‐L1+ IVLBCL group also had a significantly lower age distribution and a lower frequency of patients older than 60 years compared to the PD‐L1− group. Very recently, we speculate that there is possible link between PD‐L1+ IVLBCL and PD‐L1+ extranodal DLBCL‐NOS (eDLBCL) because features of the two groups showed overlapping. Therefore, we compared the clinicopathological characteristics of the PD‐L1+ IVLBCL and PD‐L1+ eDLBCL. There were no significant differences in clinicopathological parameters and prognosis. Conclusion The worse prognosis of the PD‐L1+ group might be caused by immune evasion mechanisms, which are linked to PD‐L1 expression. Therefore, PD‐L1+ IVLBCL cases might be regarded as good candidates for targeted immunotherapy. We also highlighted the overlapping features of PD‐L1+ IVLBCL and PD‐L1+ eDLBCL. This result suggests that they should be regarded as one entity, immune evasion‐related extranodal large B‐cell lymphoma. |
| format | Article |
| id | doaj-art-4c0f6a28f0514d4da1caa99d2011effe |
| institution | OA Journals |
| issn | 2045-7634 |
| language | English |
| publishDate | 2020-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-4c0f6a28f0514d4da1caa99d2011effe2025-08-20T02:34:49ZengWileyCancer Medicine2045-76342020-07-019134768477610.1002/cam4.3104PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapyYuka Suzuki0Kei Kohno1Kosei Matsue2Ayako Sakakibara3Eri Ishikawa4Satoko Shimada5Kazuyuki Shimada6Seiyo Mabuchi7Taishi Takahara8Seiichi Kato9Shigeo Nakamura10Akira Satou11Department of Pathology and Laboratory Medicine Nagoya University Hospital Nagoya JapanDepartment of Pathology and Laboratory Medicine Nagoya University Hospital Nagoya JapanDivision of Haematology/Oncology Department of Internal Medicine Kameda Medical Centre Kamogawa JapanDepartment of Pathology and Laboratory Medicine Nagoya University Hospital Nagoya JapanDepartment of Pathology and Laboratory Medicine Nagoya University Hospital Nagoya JapanDepartment of Pathology and Laboratory Medicine Nagoya University Hospital Nagoya JapanDepartment of Haematology and Oncology Nagoya University Graduate School of Medicine Nagoya JapanDepartment of Pathology and Laboratory Medicine Nagoya University Hospital Nagoya JapanDepartment of Surgical Pathology Aichi Medical University Hospital Nagakute JapanDepartment of Pathology and Molecular Diagnostics Aichi Cancer Centre Hospital Nagoya JapanDepartment of Pathology and Laboratory Medicine Nagoya University Hospital Nagoya JapanDepartment of Surgical Pathology Aichi Medical University Hospital Nagakute JapanAbstract Background Intravascular large B‐cell lymphoma (IVLBCL) is a rare form of diffuse large B‐cell lymphoma (DLBCL) arising in extranodal sites. PD‐L1 expression of tumor cells has been reported in IVLBCL cells, but its clinicopathological relevance remains to be elucidated. Aims This study was aimed to reveal the characteristics of PD‐L1+ IVLBCL. Methods and results Neoplastic PD‐L1 expression was examined in 34 cases of IVLBCL and clinicopathological characteristics between patients with PD‐L1+ and PD‐L1− IVLBCL were compared. We assessed PD‐L1 expression with SP142 antibody. Twelve (35%) of 34 cases showed positivity for PD‐L1. The PD‐L1+ group had significantly lower survival rates compared to the PD‐L1− group. The PD‐L1+ IVLBCL group also had a significantly lower age distribution and a lower frequency of patients older than 60 years compared to the PD‐L1− group. Very recently, we speculate that there is possible link between PD‐L1+ IVLBCL and PD‐L1+ extranodal DLBCL‐NOS (eDLBCL) because features of the two groups showed overlapping. Therefore, we compared the clinicopathological characteristics of the PD‐L1+ IVLBCL and PD‐L1+ eDLBCL. There were no significant differences in clinicopathological parameters and prognosis. Conclusion The worse prognosis of the PD‐L1+ group might be caused by immune evasion mechanisms, which are linked to PD‐L1 expression. Therefore, PD‐L1+ IVLBCL cases might be regarded as good candidates for targeted immunotherapy. We also highlighted the overlapping features of PD‐L1+ IVLBCL and PD‐L1+ eDLBCL. This result suggests that they should be regarded as one entity, immune evasion‐related extranodal large B‐cell lymphoma.https://doi.org/10.1002/cam4.3104extranodal DLBCLimmunohistochemistryintravascular large B‐cell lymphomaPD‐L1SP142 |
| spellingShingle | Yuka Suzuki Kei Kohno Kosei Matsue Ayako Sakakibara Eri Ishikawa Satoko Shimada Kazuyuki Shimada Seiyo Mabuchi Taishi Takahara Seiichi Kato Shigeo Nakamura Akira Satou PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapy Cancer Medicine extranodal DLBCL immunohistochemistry intravascular large B‐cell lymphoma PD‐L1 SP142 |
| title | PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapy |
| title_full | PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapy |
| title_fullStr | PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapy |
| title_full_unstemmed | PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapy |
| title_short | PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapy |
| title_sort | pd l1 sp142 expression in neoplastic cells predicts a poor prognosis for patients with intravascular large b cell lymphoma treated with rituximab based multi agent chemotherapy |
| topic | extranodal DLBCL immunohistochemistry intravascular large B‐cell lymphoma PD‐L1 SP142 |
| url | https://doi.org/10.1002/cam4.3104 |
| work_keys_str_mv | AT yukasuzuki pdl1sp142expressioninneoplasticcellspredictsapoorprognosisforpatientswithintravascularlargebcelllymphomatreatedwithrituximabbasedmultiagentchemotherapy AT keikohno pdl1sp142expressioninneoplasticcellspredictsapoorprognosisforpatientswithintravascularlargebcelllymphomatreatedwithrituximabbasedmultiagentchemotherapy AT koseimatsue pdl1sp142expressioninneoplasticcellspredictsapoorprognosisforpatientswithintravascularlargebcelllymphomatreatedwithrituximabbasedmultiagentchemotherapy AT ayakosakakibara pdl1sp142expressioninneoplasticcellspredictsapoorprognosisforpatientswithintravascularlargebcelllymphomatreatedwithrituximabbasedmultiagentchemotherapy AT eriishikawa pdl1sp142expressioninneoplasticcellspredictsapoorprognosisforpatientswithintravascularlargebcelllymphomatreatedwithrituximabbasedmultiagentchemotherapy AT satokoshimada pdl1sp142expressioninneoplasticcellspredictsapoorprognosisforpatientswithintravascularlargebcelllymphomatreatedwithrituximabbasedmultiagentchemotherapy AT kazuyukishimada pdl1sp142expressioninneoplasticcellspredictsapoorprognosisforpatientswithintravascularlargebcelllymphomatreatedwithrituximabbasedmultiagentchemotherapy AT seiyomabuchi pdl1sp142expressioninneoplasticcellspredictsapoorprognosisforpatientswithintravascularlargebcelllymphomatreatedwithrituximabbasedmultiagentchemotherapy AT taishitakahara pdl1sp142expressioninneoplasticcellspredictsapoorprognosisforpatientswithintravascularlargebcelllymphomatreatedwithrituximabbasedmultiagentchemotherapy AT seiichikato pdl1sp142expressioninneoplasticcellspredictsapoorprognosisforpatientswithintravascularlargebcelllymphomatreatedwithrituximabbasedmultiagentchemotherapy AT shigeonakamura pdl1sp142expressioninneoplasticcellspredictsapoorprognosisforpatientswithintravascularlargebcelllymphomatreatedwithrituximabbasedmultiagentchemotherapy AT akirasatou pdl1sp142expressioninneoplasticcellspredictsapoorprognosisforpatientswithintravascularlargebcelllymphomatreatedwithrituximabbasedmultiagentchemotherapy |